ADVANCED CELL TECHNOLOGY, INC.
Departure of Directors or Certain Officers; Appointment of Certain Officers

Advanced Cell Technology, Inc. is a biotechnology company focused on applying stem cell technology in the field of regenerative medicine. The company is focused on developing and commercializing human stem cell technology in the emerging field of regenerative medicine.

Advanced Cell’s technologies provide therapies for a broad range of diseases that include: myoblasts for treating heart failure; hemangioblasts for treating blood disorders, cardiovascular disease, and cancer; retinal pigment epithelial cells for treating macular degeneration and other retinal degenerative disorders; skin cells for dermatological conditions; neuronal cells for spinal cord injury; and liver cells for hepatitis and cirrhosis.

Advanced Cell Technology’s product folio includes: Myoblast program, an autologous adult stem cell therapy for the treatment of heart disease; Retinal Pigmented Epithelial Cell Program for the treatment of diseases of the eye, including macular degeneration; and Hemangioblast (HG) Cell Program for cardiovascular disease, stroke, and cancer. It announced positive results for its animal studies for the RPE cell program in collaboration with the Casey Eye Institute at Oregon Health and Science University.

KEY STATISTICS

<table>
<thead>
<tr>
<th>Description</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price as of 12/14/10</td>
<td>$0.14</td>
</tr>
<tr>
<td>52 Wk High – Low</td>
<td>$0.04 - $0.20</td>
</tr>
<tr>
<td>Est. FD Shares Out.</td>
<td>1.09B</td>
</tr>
<tr>
<td>Market Capitalization</td>
<td>152.35M</td>
</tr>
<tr>
<td>Volume / Avg Volume</td>
<td>22.95M/25.37M</td>
</tr>
<tr>
<td>Exchange</td>
<td>OTCBB</td>
</tr>
</tbody>
</table>

COMPANY INFORMATION

Advanced Cell Technology, Inc.
381 Plantation Street
Worcester, MA 01605
United States
www.advancedcell.com
Employees: 14

NEWS EVENTS

After the market close on Tuesday, December 14, the company officially announced that William M. Caldwell IV, the Chairman and Chief Executive Officer of Advanced Cell Technology, Inc. had unexpectedly passed away on the evening of December 13, 2010. The Company’s Board has appointed Gary Rabin, long time member of the board, to serve as the Company’s interim Chairman and Chief Executive Officer until a permanent replacement is named.

Among other recent developments, the company became only the second company in history to have the US Food and Drug Administration (FDA) clear an Investigational New Drug (IND) application involving the use of stem cells. The company continues to plan the initiation of a first-of-its-kind; open-label study human trial using Retinal cells derived from human embryonic stem cells (hESCs) seek to treat patients with Stargardt’s Macular Dystrophy (SMD).

The FDA granted Orphan Drug designation for these RPE cells. An important component of this designation is that the company is now eligible to receive tax credits, access to grant funding for additional clinical trials, allowance for marketing exclusivity for up to seven years and consideration for accelerated FDA approval.

In addition, the company announced that it has filed an Investigational New Drug (IND) Application with the US Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study using human embryonic stem cell (hESC) derived retinal pigment epithelial (RPE) cells to treat patients with Dry Age-Related Macular Degeneration.
Advanced Cell Technology, Inc. (OTCBB:ACTC)

(Dry AMD).

KEY TAKEAWAYS

The growing firm employs only 14 individuals. The remaining executives and employees have been key to helping the company achieve a number of its major milestones and are expected to remain with the company.

Management and employees appear to be well versed with the execution of the former CEO’s vision and plans for the company. Officials have stated that they are firmly committed to continuing former Chairman Caldwell’s legacy.

The company does not expect that the timing of its announced human trials and other filings and therapies will be impacted by Mr. Caldwell’s passing, and the scientific team remains intact and fully committed to ACT’s objectives and mission statements.

The following events and milestones have been noted publicly:

- Anticipated FDA approval of ACTC’s IND for Stargardt’s Disease – expected in Q1 2011
- Anticipated FDA approval of ACTC’s IND for Dry Macular Degeneration – expected in Q1 2011
- A foray into the E.U. market for both Stargardt’s and Dry AMD – expected in the first half of 2011
- Initiation of Phase 2 Trials for Myoblast heart program – using adults stem cells to treat dead heart tissue resulting from heart attacks - expected in the first half of 2011

The Board of Directors has formed a search committee to focus on identifying a permanent replacement for Mr. Caldwell.

Given all of those facts, we believe the impact of Mr. Caldwell’s passing is not expected to affect share prices or market capitalization adversely. In addition, since members of management have said that the company is on the verge of announcing several more achievements, we feel investors might be inclined to holding positions or buying on any price pullbacks.

Analysis of Strengths, Weaknesses, Opportunities and Threats

SWOT analysis of Advanced Cell Technology shows several significant findings which should be noted by current and perspective investors:

Strengths:

Strong In-house Research and Scientific Expertise

Advanced Cell Technology has successfully leverages its expertise in research and scientific activities to not only move its pipeline forward but to also expand into international markets and surpass its competitors to continuously grow in the global market. It's activities with focus on the study of human stem cell therapies had research and development expenditure relating to continuing operations were $3.53 million in 2009, $8.64 million in 2008, $12.74 million in 2007, and $9.03 million in 2006.

Dr. Robert P. Lanza, MD has been the Chief Scientific Officer of Advanced Cell Technology has led the research and scientific programs since 2007 and will continue to do so for the foreseeable future. Lanza has over 25 years of research and industrial experience in the area of stem cells and regenerative medicine and was previously the Director of Transplantation Biology at BioHybrid Technologies, Inc. from 1990 to 1998, and is an Adjunct Professor at the Institute for Regenerative Medicine, Wake Forest University School of Medicine.

The company’s research programs include: Blastomere Program, Cellular Reprogramming and Stem Cell Differentiation. The company’s pipeline activities focus on three main programs, Myoblast program, for the treatment of heart failure; Retinal Pigment Epithelium (RPE) program, for successfully treating visual dysfunction; and Hemangioblast (HG) program, for the treatment of cardiovascular disease.

Given the recent developments with the Food and Drug Administration, the next phases of clinical testing will commence shortly. Advanced Cell Technology should continue to outpace competitors and are on track to become one of the first companies to bring stem cell therapies to full commercialization in multiple, underserved, multi-billion dollar markets.

www.goldmanresearch.com
Patent Portfolio

While other, larger pharmaceutical and biotechnology companies are currently exploring possible treatments and therapies in the same areas Advanced Cell Technology’s strong patent portfolio has created market exclusivity to their proprietary drug candidates. This has given the company a competitive edge as a developing stage biotechnology company. Advanced Cell Technology has been successful in obtaining patents and other proprietary rights and are actively seeking to protect product candidates and proprietary information not only in the U.S. but also in the global markets via foreign patents, contractual arrangements and trademarks. In fact, the company’s intellectual property collectively represents one of the strongest portfolios in the field of regenerative medicine.

The company currently owns or has exclusive owned rights to 45 issued patents and 380 patent applications pending worldwide in the field of regenerative medicine and stem cell therapy. We also have non-exclusive rights to a portfolio of patents and patent applications that support our core intellectual property. We believe our intellectual property collectively represents one of the strongest portfolios in the field.

The company’s patent portfolio makes the company an attractive take-over target, especially given the current research and development environment. The portfolio should continue to rise in value as the company moves forward through the regulatory process.

Weaknesses:

Lack of revenue from product sales

Advanced Cell Technology has posted significant growth in its revenues; from $.79 million in 2008 to $1.42 million in 2009, while the company's 37.6% compounded annual growth rate for revenue (CAGR) was well above the Pharmaceuticals & Healthcare sector average* of 16.53% during 2005-2009.

However, Advanced Cell Technology’s inability to generate revenue from product sales has increased its dependence on various agreements and collaboration, to sustain its economic strength. This is the norm for early-stage biotechnology companies, with all its potential products under clinical trials.

Substantial expenditures for the development and commercialization have resulted in huge losses for the company but management has reduced debentures to under $900,000 by eliminating over $33 million in debentures in the last fifteen months. Basic debenture financings which were done by the company from 2005 to 2010 have been mostly extinguished. The company expects to incur additional expenses as it continues to undertake testing for its drug candidates, and seek regulatory. Management has announced that they have $10 million in cash and credit lines available and that they are comfortable that these funds can be used to advance their programs through 2011 and into 2012.

Opportunities:

The increasing number of people aged above 65, who seek and consume disproportionately more medicines and are more prone to chronic diseases, holds significant market potential for Advanced Cell Technology. The company recognized this opportunity and has done an outstanding job of focusing their development pipeline to serving the needs of this growing demographic.

Orphan Drug Designation for RPE Cells

Orphan Drug designation for Advanced Cell Technology’s lead drug candidate, MA09-hRPE cells, has served to underscore the need for improved therapies in Stargardt’s Macular Dystrophy (SMD). The company is committed to pursuing large areas of unmet need.

Earlier this year (March 2010) the company was assigned an Orphan Drug Status designation from the U.S. Food and Drug Administration for its lead product candidate, MA09-hRPE cells, for the treatment of Stargardt’s Macular Dystrophy, an eye condition, which affects the central area of the retina called the macula. This Orphan Drug designation is important because it will not only help in the speedy development and commercialization of the drug candidate, but also provides several benefits to the company including reduced costs for clinical trials, reduced fees while filing MAA and up to 50% tax incentive on clinical development costs, seven years market exclusivity in the US and 10 years in Europe.
Market Potential for treatment of Age-related Macular Degeneration

Advanced Cell Technology is it focused on developing the retinal pigment epithelium (RPE) program for the treatment of age-related macular degeneration (AMD). This represents a growing $28 billion market which could provide significant growth opportunities to the company. Each year, more than 30 million people suffer from one or the other diseases of eye and a number of potential growth prospects, driven primarily by the increasing patient population and lack of effective treatment alternatives, exist. Currently approved therapies only treat the condition, but do not regenerate the damaged cells of the macula. Existing therapies are only effective in the treatment of Wet AMD but not for Dry AMD. This leaves about 90% of the potential AMD patient pool without access to effective treatments.

Market Potential for the treatment of Heart Failure

A considerable market potential exists for Advanced Cell Technology’s therapy candidates for the treatment of heart failure (HF). The company is focused on a late stage clinical trial product for the treatment of heart failure which can help the more than 5.7 million Americans who are estimated to suffer from heart failure. With 670,000 new cases of heart failure diagnosed each year, Worldwide, heart failure impacts an estimated 80 million people while causing approximately 30% of all deaths. Currently, heart transplants are the only existing cure for late-stage chronic heart failure. Results of Advanced Cell Technology’s Phase I clinical trials have clearly demonstrated initial positive outcomes as to improve the lives of Stage III-IV patients in the advanced stages of the disease, without the downside of expenses and risks of heart replacement surgery. The Phase 1 trials marked the first time in the United States that scientists performed controlled, randomized clinical trials using catheter-delivered muscle stem cells to treat congestive heart failure.

Partnership Agreements & Collaborations

The company has established and nourishes collaboration and agreements with other companies to enhance its business operations and bring non-dilutive capital into the company as part of its core business strategy. As the company’s drug candidates proceed through the regulatory process, we believe these types of opportunities will increase significantly.

During 2008-2009, the company entered into numerous agreements and formed major strategic collaborations. These include licensing agreement with CHA Biotech, Co., Ltd. (May 2009), whereby the company licensed its proprietary single blastomere technology to CHA Bio, for the exclusive development and commercialization in Korea; license agreement worth $2.5 million with Ireland-based Transition Holdings, Inc (December 2008), for certain of its non-core technology; and licensing agreement with Pharming Technologies B.V. (February, 2008), whereby Pharming was provided with the exclusive rights to certain patents including oocyte activation patents, for all uses and applications in or related to non-human animals. Other significant agreements in 2008 include, catheter supply agreement with Biologics Delivery Systems Group (March 2008), for the supply of catheters for the Phase II human clinical trial of ACT’s myoblast therapy in the treatment of heart failure; and a clinical trial agreement with Chandler Regional Medical Center and Mercy Gilbert Medical Center, and members of Catholic Healthcare West (CHW) (March 2008), to become ACT’s first clinical trial sites for Phase II myoblast study. Additionally, in December 2008, the company’s joint venture with CHA Biotech Co, Ltd. was named Stem Cell & Regenerative Medicine International.

Threats:

Operation and Competitors in a Highly Regulated Environment

Adverse or inconclusive results from preclinical testing or clinical trials may substantially delay, or halt, the development of the Advanced Cell Technology’s various product candidates, consequently affecting its timeliness for profitability. In addition, the company’s markets are characterized by intense competition and evolving industry standards. The company’s competitors include major pharmaceutical and biotechnology companies. Among them: Geron Corporation, Aastrom Biosciences, Inc., StemCells, Inc., Bioheart, Inc., Osiris Therapeutics, Inc., Genzyme Corporation, and ViaCell, Inc. In addition, Advanced Cell does business in a highly regulated industry, where a variety of statutes and regulations are in place. Failure to comply with the present or future regulations related to clinical, laboratory and manufacturing practices may result in delayed approval of drugs, product recalls, and cancellation of permission to produce or sell the drugs.

www.goldmanresearch.com
About Goldman Small Cap Research

Goldman Small Cap Research was founded by Rob Goldman who has 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell-side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.’s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.

Disclaimer

This news analysis report was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports. It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. While stocks in the Opportunity format may have a higher risk profile, they typically offer greater upside as well. As a Select Research product, the Company has not been compensated for the preparation, production, or release of this report. All information contained in this report was provided by the Company, or analyst derived due diligence. Goldman Small Cap Research analysts are responsible only to the public, and retain full editorial control over its research products.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This report does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor's decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: http://goldmanresearch.com/index.php

www.goldmanresearch.com